Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

231
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
231
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.1K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Icotrokinra: First Approval.

Drugs·2026
Same author

Ferric Maltol: Pediatric First Approval.

Paediatric drugs·2026
Same author

Sevabertinib: First Approval.

Drugs·2026
Same author

Retlirafusp Alfa: First Approval.

Drugs·2026
Same author

Zeprumetostat: First Approval.

Drugs·2025
Same author

Brensocatib: First Approval.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

Intubation-mediated Intratracheal IMIT Instillation: A Noninvasive, Lung-specific Delivery System
08:00

Intubation-mediated Intratracheal IMIT Instillation: A Noninvasive, Lung-specific Delivery System

Published on: November 17, 2014

25.2K

Imlunestrant: First Approval.

Susan J Keam1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand. dru@adis.com.

Drugs
|December 3, 2025
PubMed
Summary
This summary is machine-generated.

Imlunestrant is a new oral treatment for ER+, HER2-, ESR1-mutated advanced breast cancer. It received US approval in September 2025 after progressing on prior endocrine therapy.

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.9K
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

10.7K

Related Experiment Videos

Last Updated: Jan 9, 2026

Intubation-mediated Intratracheal IMIT Instillation: A Noninvasive, Lung-specific Delivery System
08:00

Intubation-mediated Intratracheal IMIT Instillation: A Noninvasive, Lung-specific Delivery System

Published on: November 17, 2014

25.2K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.9K
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

10.7K

Area of Science:

  • Oncology
  • Pharmacology
  • Endocrinology

Background:

  • Estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer is a major subtype.
  • Estrogen receptor 1 (ESR1) mutations are common in advanced ER+ breast cancer and confer resistance to endocrine therapy.
  • Selective estrogen receptor degraders (SERDs) represent a targeted approach for these patients.

Purpose of the Study:

  • To summarize the development milestones of imlunestrant.
  • To highlight the regulatory approval of imlunestrant for a specific breast cancer subtype.

Main Methods:

  • Review of preclinical and clinical development data for imlunestrant.
  • Analysis of regulatory submission and approval process in the USA.

Main Results:

  • Imlunestrant, an oral SERD, demonstrated efficacy in ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.
  • US FDA approval granted in September 2025 for patients with disease progression after endocrine therapy.

Conclusions:

  • Imlunestrant offers a new oral treatment option for a difficult-to-treat breast cancer population.
  • The development of imlunestrant signifies progress in targeted therapies for endocrine-resistant breast cancer.